SM
PVLA

Sabby Management’s Palvella Therapeutics PVLA Stock Holding History

Sabby Management’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-16,200
Closed -$1.81M – 326
2016
Q4 		$1.81M Sell
16,200
-3,091
-16% -$383K 0.11% 109
2016
Q3 		$2.82M Sell
19,291
-909
-5% -$121K 0.11% 103
2016
Q2 		$2.6M Buy
20,200
+18,012
+823% +$2.76M 0.14% 88
2016
Q1 		$333K Buy
2,188
+1,248
+133% +$176K 0.02% 238
2015
Q4 		$172K Sell
940
-944
-50% -$158K 0.01% 286
2015
Q3 		$276K Buy
+1,884
New +$420K 0.01% 330

Other funds holding PVLA

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $727M AUM 41.88% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
EI
EAM Investors Solana Beach, California $1.12B AUM 390.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sabby Management's PVLA Position: Q1 2017 in Review

Sabby Management sold out of Palvella Therapeutics (PVLA) in Q1 2017, closing a stake of 16,200 shares — an estimated $1.81M sold.

Sabby Management first reported a position in PVLA in Q3 2015 and held it in 6 quarters. The position peaked at $2.82M in Q3 2016. 27 funds tracked by Wall St. Rank hold PVLA as of Q1 2017.

  • Sabby Management reported no remaining Palvella Therapeutics position as of Q1 2017 after selling out during the quarter.
  • Sabby Management sold 16,200 Palvella Therapeutics shares in Q1 2017, an estimated $1.81M.
  • Sabby Management first reported a position in Palvella Therapeutics in Q3 2015 and held it in 6 quarters.
  • Sabby Management's Palvella Therapeutics position peaked at $2.82M in Q3 2016.
  • 27 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q1 2017.

Based on Sabby Management's 13F filing for Q1 2017, filed 15 May 2017.